Advertisement
Feature Article

Codeine and headache. ‘Doctor, I just need a script for my headaches’

Shuli Cheng, Elspeth Hutton
OPEN ACCESS

Each of these should be used for a maximum of 15 days per month. 

Trigeminal autonomic cephalgia 

Trigeminal autonomic cephalgia includes cluster headache, hemicrania continua and paroxysmal hemicranias. These are a group of rare headache disorders that, if suspected, should prompt patient referral to a neurologist for diagnosis and management. All are characterised by:

  • a strictly one-sided headache 
  • with associated (typically ipsilateral) autonomic features, such as tearing, conjunctival injection, ptosis, rhinorrhoea, tinnitus, unilateral facial flushing or sweating.

Cluster headache is one of the most severe pains described, and the patient should be referred urgently so that optimal management can be initiated. If the patient experiences frequent episodes then consider starting verapamil 40 to 80mg three times daily while awaiting specialist review. Acute attacks may respond to subcutaneous sumatriptan, a rizatriptan wafer or intranasal sumatriptan. High-flow oxygen (100% at 12 to 15L/min by non-rebreather mask) can also abort an acute attack.

Advertisement
Advertisement

Conclusion

The strategy to manage a patient with headache and codeine dependence is to diagnose the primary headache disorder and direct appropriate treatment towards this, including preventive medications where appropriate. Medication overuse should be addressed concurrently. Codeine should be weaned over seven to 10 days, with bridging therapy if needed. Lifestyle advice is integral to management in this group of patients.     M

 

Advertisement
Advertisement

COMPETING INTERESTS: Dr Cheng has received fellowship funding from Allergan and is involved in clinical trials sponsored by Teva. Dr Hutton has sat on advisory boards for Novartis, Teva and Sanofi-Genzyme; has received speaker's fees from Allergan, Biogen, Sanofi-Genzyme and Teva; and is involved in clinical trials sponsored by Teva and Novartis. 

 

References

1.    O’Sullivan E, Sweeney B, Mitten E, Ryan C. Headache management in community pharmacies. Ir Med J 2016; 109: 373.
2.    Bigal M, Serrano D, Buse D, Scher A, Stewart W, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48: 1157-1168.
3.    Bigal M, Lipton RB. Modifiable risk factors  for migraine progression. Headache 2006; 46: 1334-1343.
4.    Lipton RB. Chronic migraine, classification, differential diagnosis and epidemiology. Headache 2011; 51 Suppl 2: 77-83.
5.    Hagen K, Albretsen C, Vilmig S, et al. Management of medication overuse headache: 1year randomized multicentre open-label trial. Cephalalgia 2009; 29: 221-232.
6.    Sehgal N, Colson J, Smith HS. Chronic pain treatment with opioid analgesics: benefits versus harms of long term therapy. Expert Rev Neurother 2013; 13: 1201-1220. 
7.    Group NE. Headache and facial pain. Therapeutic guidelines: neurology. Version 5. Melbourne: Therapeutic Guidelines Ltd; 2017. pp. 35-69.
 

Pages

Dr Cheng is a Neurologist at Alfred Health, Melbourne. Dr Hutton is a Neurologist at Alfred Health, Melbourne; and Research Fellow in the Neurosciences Department, Monash University, Melbourne, Vic.